MDxHealth SA is a Belgium-based company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. The Company’s offerings are structured into two divisions: Clinical Molecular Diagnostics (ClinicalMDx) solutions, providing physicians with tests which aid in the identification and treatment of their cancer patients, and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions, collaborating with pharmaceutical companies on the development of companion diagnostics, biomarker discovery, and clinical trial testing. Its ClinicalMDx solutions include four different product types: ConfirmMDx, InformMDx, RecurMDx and PredictMDx. MDxHealth‘s PharmacoMDx services, provided to both existing collaborators and on contracted services basis, focus on the identification and development of epigenetic biomarkers and molecular tests into companion diagnostics. The Company has one wholly owned subsidiary, MDxHealth Inc.